Advertisement
Canada markets closed

  • S&P/TSX

    21,807.37
    +98.93 (+0.46%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CAD/USD

    0.7275
    +0.0012 (+0.16%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • Bitcoin CAD

    88,282.05
    +844.49 (+0.97%)
     

  • CMC Crypto 200

    1,385.54
    +72.91 (+5.56%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • RUSSELL 2000

    1,947.66
    +4.70 (+0.24%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,282.01
    -319.49 (-2.05%)
     

  • VOLATILITY

    18.71
    +0.71 (+3.94%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Today’s Research Reports on Stocks to Watch: Infinity Pharmaceuticals and Synergy Pharmaceuticals

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Both Infinity Pharmaceuticals and Synergy Pharmaceuticals closed in the red on Friday. Shares of Infinity closed down nearly 14% despite encouraging results reported on its Phase 1 clinical trial of IPI-549. Shares of Synergy lost about 8% after reporting a loss in its Q3 report.

RDI Initiates Coverage on:

Infinity Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=INFI

Synergy Pharmaceuticals Inc.
https://rdinvesting.com/news/?ticker=SGYP

Infinity Pharmaceuticals, Inc. shares closed down almost 14% on Friday on about 3.3 million shares. It was on Friday that the pharma company announced encouraging Phase 1 clinical and translational data for IPI-549, an oral, selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibitor that targets immune-suppressive tumor macrophages. David Hong, M.D., Deputy Chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, stated, "As the majority of patients treated with IPI-549 monotherapy have advanced forms of cancer and received several therapies prior to enrollment in this study, it's very encouraging that 44 percent of patients stayed on treatment for at least 16 weeks, including a patient with a partial response who has remained on treatment for over a year and continues on study today." He continued, "There is a significant need for better treatment options for patients, especially for patients who do not respond to or develop resistance to, existing immunotherapies as well as for types of cancer where there is limited benefit from treatment with checkpoint inhibitors. Selective inhibition of PI3K-gamma is emerging as an exciting new approach to inducing an immune response, and I look forward to my continued participation in this study."

ADVERTISEMENT

Access RDI's Infinity Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=INFI

Synergy Pharmaceuticals Inc. shares closed down 8.42% on a little over 20 million shares traded. Trading volume skyrocketed compared to the stock's average of just under 5.5 million shares. The company saw its shares to fall after posting a loss in its third-quarter financial report. The company reported a loss of $48.9 million for the period. On a per share basis it was a loss of 22 cents, which beat the loss of 27 cents that analysts had been waiting for. Revenue, however, was a miss at $5 million compared to the $5.8 million that was expected by Wall Street. The company's CEO Gary S. Jacob commented, "We remain very excited by the continued positive momentum for TRULANCE in the CIC market. The investments we've made and the continued execution of our commercial strategy have allowed us to drive strong early customer demand, gaining TRULANCE coverage on major commercial, Medicare Part D and Medicaid plans within the first six months of launch. Our progress in market access demonstrates that payers recognize the potential value TRULANCE can offer CIC patients, which we will leverage as we move towards the anticipated expansion of the label with the IBS-C indication this coming January. With growing customer demand, improved market access and the expected expansion into IBS-C, Synergy has a significant opportunity to drive further growth and long-term value for patients, healthcare providers and our shareholders." TRULANCE (plecanatide) is a once-daily tablet approved for adults with CIC and is being evaluated for IBS-C.

Access RDI's Synergy Pharmaceuticals Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SGYP

Our Actionable Research on Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com